272 related articles for article (PubMed ID: 23259601)
1. Transition States, analogues, and drug development.
Schramm VL
ACS Chem Biol; 2013 Jan; 8(1):71-81. PubMed ID: 23259601
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic Transition States and Drug Design.
Schramm VL
Chem Rev; 2018 Nov; 118(22):11194-11258. PubMed ID: 30335982
[TBL] [Abstract][Full Text] [Related]
3. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.
King NM; Melnick L; Prabu-Jeyabalan M; Nalivaika EA; Yang SS; Gao Y; Nie X; Zepp C; Heefner DL; Schiffer CA
Protein Sci; 2002 Feb; 11(2):418-29. PubMed ID: 11790852
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
Rano TA; Cheng Y; Huening TT; Zhang F; Schleif WA; Gabryelski L; Olsen DB; Kuo LC; Lin JH; Xu X; Olah TV; McLoughlin DA; King R; Chapman KT; Tata JR
Bioorg Med Chem Lett; 2000 Jul; 10(14):1527-30. PubMed ID: 10915042
[TBL] [Abstract][Full Text] [Related]
5. Transition States and transition state analogue interactions with enzymes.
Schramm VL
Acc Chem Res; 2015 Apr; 48(4):1032-9. PubMed ID: 25848811
[TBL] [Abstract][Full Text] [Related]
6. Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs.
Kuznetsov NA; Kozyr AV; Dronina MA; Smirnov IV; Kaliberda EN; Mikhailova AG; Rumsh LD; Fedorova OS; Gabibov AG; Kolesnikov AV
Dokl Biochem Biophys; 2011; 440():239-43. PubMed ID: 22095129
[No Abstract] [Full Text] [Related]
7. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.
Olsen DB; Stahlhut MW; Rutkowski CA; Schock HB; vanOlden AL; Kuo LC
J Biol Chem; 1999 Aug; 274(34):23699-701. PubMed ID: 10446127
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic transition states and transition state analogues.
Schramm VL
Curr Opin Struct Biol; 2005 Dec; 15(6):604-13. PubMed ID: 16274984
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
Wlodawer A; Vondrasek J
Annu Rev Biophys Biomol Struct; 1998; 27():249-84. PubMed ID: 9646869
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.
Raghavan S; Yang Z; Mosley RT; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Kuo LC; Emini EA; Chapman KT; Tata JR
Bioorg Med Chem Lett; 2002 Oct; 12(20):2855-8. PubMed ID: 12270162
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Kuhnert M; Steuber H; Diederich WE
J Med Chem; 2014 Jul; 57(14):6266-72. PubMed ID: 25006983
[TBL] [Abstract][Full Text] [Related]
12. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
[TBL] [Abstract][Full Text] [Related]
13. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic transition states: thermodynamics, dynamics and analogue design.
Schramm VL
Arch Biochem Biophys; 2005 Jan; 433(1):13-26. PubMed ID: 15581562
[TBL] [Abstract][Full Text] [Related]
15. Solid phase synthesis of indinavir and its analogues.
Cheng Y; Lu Z; Chapman KT; Tata JR
J Comb Chem; 2000; 2(5):445-6. PubMed ID: 11029167
[No Abstract] [Full Text] [Related]
16. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
17. Hybrid QM/MM Free-Energy Evaluation of Drug-Resistant Mutational Effect on the Binding of an Inhibitor Indinavir to HIV-1 Protease.
Taguchi M; Oyama R; Kaneso M; Hayashi S
J Chem Inf Model; 2022 Mar; 62(5):1328-1344. PubMed ID: 35212226
[TBL] [Abstract][Full Text] [Related]
18. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state].
Kiso Y
Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066
[No Abstract] [Full Text] [Related]
19. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates.
Song M; Rajesh S; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2001 Sep; 11(18):2465-8. PubMed ID: 11549448
[TBL] [Abstract][Full Text] [Related]
20. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
